JP2023156353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023156353A5 JP2023156353A5 JP2023121818A JP2023121818A JP2023156353A5 JP 2023156353 A5 JP2023156353 A5 JP 2023156353A5 JP 2023121818 A JP2023121818 A JP 2023121818A JP 2023121818 A JP2023121818 A JP 2023121818A JP 2023156353 A5 JP2023156353 A5 JP 2023156353A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- isolated
- amino acid
- purified peptide
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 230000004927 fusion Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017903381 | 2017-08-22 | ||
| AU2017903381A AU2017903381A0 (en) | 2017-08-22 | Screening Assays, Modulators and Modulation of Activation of Receptor For Advanced Glycation End-Products (RAGE) | |
| AU2018902298A AU2018902298A0 (en) | 2018-06-26 | Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE) | |
| AU2018902298 | 2018-06-26 | ||
| PCT/AU2018/050883 WO2019036753A1 (en) | 2017-08-22 | 2018-08-21 | SCREENING TESTS, MODULATORS AND MODULATION OF RECEIVER ACTIVATION FOR ADVANCED GLYCATION TERMINAL PRODUCTS (RAGE) |
| JP2020511214A JP2020531514A (ja) | 2017-08-22 | 2018-08-21 | 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511214A Division JP2020531514A (ja) | 2017-08-22 | 2018-08-21 | 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023156353A JP2023156353A (ja) | 2023-10-24 |
| JP2023156353A5 true JP2023156353A5 (enExample) | 2024-02-21 |
Family
ID=65438276
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511214A Pending JP2020531514A (ja) | 2017-08-22 | 2018-08-21 | 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節 |
| JP2023121818A Pending JP2023156353A (ja) | 2017-08-22 | 2023-07-26 | 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511214A Pending JP2020531514A (ja) | 2017-08-22 | 2018-08-21 | 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12060408B2 (enExample) |
| EP (1) | EP3672982A4 (enExample) |
| JP (2) | JP2020531514A (enExample) |
| CN (2) | CN111247163B (enExample) |
| AU (1) | AU2018322482B2 (enExample) |
| CA (1) | CA3109871A1 (enExample) |
| WO (1) | WO2019036753A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018322482B2 (en) * | 2017-08-22 | 2024-04-04 | Monash University | Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (RAGE) |
| KR102203850B1 (ko) * | 2019-04-09 | 2021-01-18 | 사회복지법인 삼성생명공익재단 | 신경교종의 진단 또는 예후 예측용 조성물 및 이에 관한 정보를 제공하는 방법 |
| WO2021262601A1 (en) | 2020-06-22 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Treatment of obesity with g-protein coupled receptor 75 (gpr75) inhibitors |
| WO2022150709A1 (en) * | 2021-01-11 | 2022-07-14 | President And Fellows Of Harvard College | Compositions and methods for treating viral infection |
| CN113293212A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用 |
| CN113789379B (zh) * | 2021-08-30 | 2022-08-23 | 远见生物科技（上海）有限公司 | 一种检测前列腺癌的诊断试剂盒及其检测方法与应用 |
| JP2023084477A (ja) * | 2021-12-07 | 2023-06-19 | 花王株式会社 | 硫黄化合物を原因とするにおいの抑制剤の評価及び／又は選択方法 |
| KR20230147988A (ko) * | 2022-04-15 | 2023-10-24 | 아주대학교산학협력단 | Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물 |
| WO2024044659A1 (en) * | 2022-08-24 | 2024-02-29 | Tectonic Therapeutic, Inc. | Constitutively active g protein-coupled receptor compositions and methods of use thereof |
| CN118777620A (zh) * | 2023-04-07 | 2024-10-15 | 浙江友宁生物医药科技有限公司 | Gpr139受体激活检测方法、生理功能评价方法及应用 |
| CN116410335B (zh) * | 2023-04-24 | 2024-08-13 | 徐州医科大学 | 一种多肽tat-mrgprx1c及其应用 |
| CN118755834B (zh) * | 2024-07-15 | 2025-11-18 | 河北医科大学第四医院（河北省肿瘤医院） | 胃癌复发预测模型 |
| CN119901926A (zh) * | 2025-03-31 | 2025-04-29 | 浙江省立同德医院(浙江省精神卫生研究院) | 一种基于rage过表达和spr技术的rage靶向药物筛选方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0608401A2 (pt) | 2005-03-17 | 2010-11-16 | Columbia Univ New York | polipeptìdeo, composição farmacêutica, ácido nucleico, vetor de expressão, célula, métodos para inibir a ligação entre diáfano e o domìnio citoplasmático de rage, para identificar um agente que inibe a ligação entre o diáfano e o domìnio citoplasmático de rage, e, uso de um agente que inibe a ligação entre diáfano e o domìnio citoplasmático de rage |
| AU2018322482B2 (en) * | 2017-08-22 | 2024-04-04 | Monash University | Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (RAGE) |
-
2018
- 2018-08-21 AU AU2018322482A patent/AU2018322482B2/en active Active
- 2018-08-21 CN CN201880068213.4A patent/CN111247163B/zh active Active
- 2018-08-21 US US16/641,174 patent/US12060408B2/en active Active
- 2018-08-21 WO PCT/AU2018/050883 patent/WO2019036753A1/en not_active Ceased
- 2018-08-21 EP EP18849151.8A patent/EP3672982A4/en active Pending
- 2018-08-21 CA CA3109871A patent/CA3109871A1/en active Pending
- 2018-08-21 JP JP2020511214A patent/JP2020531514A/ja active Pending
- 2018-08-21 CN CN202411603566.3A patent/CN120607606A/zh active Pending
-
2023
- 2023-07-26 JP JP2023121818A patent/JP2023156353A/ja active Pending
-
2024
- 2024-08-13 US US18/802,964 patent/US20250019415A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023156353A5 (enExample) | ||
| JP2019535268A5 (ja) | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2002500043A5 (enExample) | ||
| JP2012082206A5 (enExample) | ||
| JP2002502589A5 (enExample) | ||
| JP2020503262A5 (ja) | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2019506166A5 (enExample) | ||
| JP2018538356A5 (enExample) | ||
| JP2018537087A5 (enExample) | ||
| JP2015527882A5 (enExample) | ||
| JP2009520463A5 (enExample) | ||
| WO2014081702A4 (en) | Synthetic linear apelin mimetics for the treatment of heart failure | |
| JP2016501851A5 (enExample) | ||
| JP2002514418A5 (enExample) | ||
| WO2012122464A1 (en) | Methods and compositions for modulating tnf/tnfr signaling | |
| FI4034555T3 (fi) | Dap10/dap12-fuusiopolypeptidit | |
| JP2020517260A5 (enExample) | ||
| JP2023116739A5 (enExample) | ||
| RU2010141916A (ru) | Растворимый мутант рецептора фактора некроза опухоли | |
| JP2004505640A5 (enExample) | ||
| JP2004537284A5 (enExample) | ||
| JP2001515720A (ja) | β−デフェンシン | |
| JPWO2021191447A5 (enExample) | ||
| JP2002539829A5 (enExample) | ||
| AU779261B2 (en) | Bone stimulating factor |